Clinical trial

IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis

NCT00488839

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2007-06-01

PhasePHASE3

Study timeline

Study start (unknown)2007-06-01Date precision: month

Registry last updated2019-11-06

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Multiple Sclerosisunresolved

Interventions

IPX056 20 mgDRUG

IPX056 40 mgDRUG

Encapsulated Baclofen 20 mgDRUG

Placebo Baclofen TabletDRUG

IPX056 10 mgDRUG

IPX056 30 mgDRUG

IPX056 35 mgDRUG

Placebo IPX056 20 mgDRUG

Placebo IPX056 40 mgDRUG

Sponsors & collaborators

Impax Laboratories, LLClead sponsor

Mapped research locations

Little RockArkansas, United States2 AtlantaGeorgia, United States1 San AntonioTexas, United States1 TampaFlorida, United States1 MontrealQuebec, Canada1 Ann ArborMichigan, United States1 RichmondVirginia, United States1 TucsonArizona, United States1 Colorado SpringsColorado, United States1 HollywoodFlorida, United States1 PeoriaIllinois, United States1 KyivUkraine1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00488839 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.